WTA to Require Genetic Sex Testing for All Tour Players

The Women’s Tennis Association (WTA) will require all players to undergo genetic sex testing to compete on the WTA Tour, according to a report by BBC Sport on July 20, 2026. This mandate establishes a standardized biological screening process for athletes seeking entry into the professional women’s circuit.

WTA Genetic Testing Mandate for Tour Players

The decision by the WTA to implement genetic sex testing marks a shift in how the governing body verifies eligibility for its female-only competition. According to BBC Sport, the requirement applies to all players who wish to maintain or gain status on the WTA Tour.

The policy focuses on genetic markers to determine eligibility, moving beyond previous methods of verification. While the WTA has not detailed the specific genetic markers being screened, the requirement is presented as a prerequisite for professional competition within the organization.

Impact on Player Eligibility and Competition

The introduction of mandatory genetic testing creates a new compliance hurdle for athletes. Under the reported guidelines, players who do not undergo the testing or who do not meet the genetic criteria established by the WTA will be ineligible to compete in tour-level events.

This development follows a broader trend in international sports where governing bodies have increasingly utilized biological and genetic data to define category boundaries. The WTA’s move aligns the tour with stricter eligibility protocols seen in other high-performance sporting federations.

The timing of this announcement, July 20, 2026, places the requirement at the forefront of the tour’s regulatory framework. Players must now coordinate with the WTA to ensure their biological documentation is current and verified to avoid missing scheduled tournaments.